Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: Angiopeptin; Lanreotide; Somatostatin

Criteria

Inclusion Criteria:

• digestive obstruction located in the upper part of the gastro-intestinal tract

• digestive obstruction of malignant origin

• peritoneal carcinomatosis confirmed by a CT Scan

• at least two vomiting episodes per day or a presence of a nasogastric suction tube

• inoperable patients

Exclusion Criteria:

• specific anticancer therapy within the previous 15 days

• signs of bowel perforation

• somatostatin or any analogue as treatment of the bowel obstruction